Laboratory assays for Epstein-Barr virus-related disease

Journal of Molecular Diagnostics

Volumn 10, Issue 4, 2008, Pages 279-292

  Gulley, Margaret L ^a   Tang, Weihua ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

CELL TYPE; EPSTEIN BARR VIRUS; GENE STRUCTURE; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; INFECTIOUS MONONUCLEOSIS; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIMARY INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY; STOMACH ADENOCARCINOMA; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN;

HUMAN HERPESVIRUS 4;

EID: 47749088247     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2008.080023     Document Type: Review

References (146)

1. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA: Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999, 190:567-576
2. Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, Jabs WJ: Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol 2003, 41:5419-5428
3. Gulley ML, Fan H, Elmore SH: Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting. J Mol Diagn 2006, 8:589-597
4. Fafi-Kremer S, Morand P, Brion JP, Pavese P, Baccard M, Germi R, Genoulaz O, Nicod S, Jolivet M, Ruigrok RW, Stahl JP, Seigneurin JM: Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J Infect Dis 2005, 191:985-989
5. Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH: X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol 1999, 73:1555-1564
6. Frangou P, Buettner M, Niedobitek G: Epstein-Barr virus (EBV) infection in epithelial cells in vivo: rare detection of EBV replication in tongue mucosa but not in salivary glands. J Infect Dis 2005, 191:238-242
7. Halvorsen JA, Brevig T, Aas T, Skar AG, Slevolden EM, Moi H: Genital ulcers as initial manifestation of Epstein-Barr virus infection: two new cases and a review of the literature. Acta Dermatol Venereol 2006, 86:439-442
8. Thomas R, Macsween KF, McAulay K, Clutterbuck D, Anderson R, Reid S, Higgins CD, Swerdlow AJ, Harrison N, Williams H, Crawford DH: Evidence of shared Epstein-Barr viral isolates between sexual partners, and low level EBV in genital secretions. J Med Virol 2006, 78:1204-1209
9. Kusuhara K, Takabayashi A, Ueda K, Hidaka Y, Minamishima I, Take H, Fujioka K, Imai S, Osato T: Breast milk is not a significant source for early Epstein-Barr virus or human herpesvirus 6 infection in infants: a seroepidemiologic study in 2 endemic areas of human T-cell lymphotropic virus type I in Japan. Microbiol Immunol 1997, 41:309-312
10. Raab-Traub N, Flynn K: The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986, 47:883-889
11. Gulley ML, Pulitzer DR, Eagan PA, Schneider BG: Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996, 27:20-27
12. Locker J, Nalesnik M: Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989, 135:977-987
13. Reisinger J, Rumpler S, Lion T, Ambros PF: Visualization of episomal and integrated Epstein-Barr virus DNA by fiber fluorescence in situ hybridization. Int J Cancer 2006, 118:1603-1608
14. Thorley-Lawson DA, Duca KA, Shapiro M: Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality. Trends Immunol 2008, 29:195-201
15. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG: Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997, 94:12616-12621
16. Niens M, Jarrett RF, Hepkema B, Nolte IM, Diepstra A, Platteel M, Kouprie N, Delury CP, Gallagher A, Visser L, Poppema S, te Meerman GJ, van den Berg A: HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 2007, 110:3310-3315
17. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, Dorfman RF, Mann RB, Ambinder RF: Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005, 23:7604-7613
18. Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS, Freeland J, Taylor GM, Taylor PR: Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 2005, 106:2444-2451
19. van Beek J, Brink AA, Vervoort MB, van Zijp MJ, Meijer CJ, van den Brule AJ, Middeldorp JM: In vivo transcription of the Epstein-Barr virus (EBV) BamHI-A region without associated in vivo BARF0 protein expression in multiple EBV-associated disorders. J Gen Virol 2003, 84:2647-2659
20. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR: Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006, 2:e23
21. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer DP, Harrington WJ Jr: EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 2008, 68:1436-1442
22. Bhaduri-McIntosh S, Rotenberg MJ, Gardner B, Robert M, Miller G: Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood 2008, 111:1334-1343
23. Zeytinoglu A, Altuglu I, Karatas E, Yazan Sertoz R: Comparison of immunofluorescence assay and multiplexed microparticle-based immunoassay for detecting Epstein-Barr virus viral capsid antigen antibodies. J Virol Methods 2008, 148:300-302
24. Gartner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, Mueller-Lantzsch N: Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol 2003, 10:78-82
25. Luderer R, Kok M, Niesters HG, Schuurman R, de Weerdt O, Thijsen SF: Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation. MoI Diagn 2005, 9:195-200
26. de Sanjose S, Bosch R, Schouten T, Verkuijlen S, Nieters A, Foretova L, Maynadie M, Cocco PL, Staines A, Becker N, Brennan P, Benavente Y, Boffetta P, Meijer CJ, Middeldorp JM: Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. Int J Cancer 2007, 121:1806-1812
27. Deng H, Zeng Y, Lei Y, Zhao Z, Wang P, Li B, Pi Z, Tan B, Zheng Y, Pan W: Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chinese Med Journal 1995, 108:300-303
28. Fan H, Nicholls J, Chua D, Chan KH, Sham J, Lee S, Gulley ML: Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 2004, 112:1036-1041
29. Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM: Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol 2007, 79:1710-1721
30. Chan KH, Gu YL, Ng F, Ng PS, Seto WH, Sham JS, Chua D, Wei W, Chen YL, Luk W, Zong YS, Ng MH: EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 2003, 105:706-709
31. Tierney RJ, Edwards RH, Sitki-Green D, Croom-Carter D, Roy S, Yao QY, Raab-Traub N, Rickinson AB: Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis 2006, 193:287-297
32. Pai PC, Tseng CK, Chuang CC, Wei KC, Hao SP, Hsueh C, Chang KP, Tsang NM: Polymorphism of C-terminal activation region 2 of Epstein-Barr virus latent membrane protein 1 in predicting distant failure and post-metastatic survival in patients with nasopharyngeal carcinoma. Head Neck 2007, 29:109-119
33. Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML: Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn 2004, 6:378-385
34. Chan KC, Yeung SW, Lui WB, Rainer TH, Lo YM: Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem 2005, 51:781-784
35. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM: Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003, 63:2028-2032
36. Ryan JL, Fan H, Swinnen LJ, Schichman SA, Raab-Traub N, Covington M, Elmore S, Gulley ML: Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 2004, 13:61-68
37. Gulley ML, Glaser SL, Craig FE, Borowitz M, Mann RB, Shema SJ, Ambinder RF: Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol 2002, 117:259-267
38. Glaser SL, Hsu JL, Gulley ML: Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev 2004, 13:688-697
39. Junying J, Herrmann K, Davies G, Lissauer D, Bell A, Timms J, Reynolds GM, Hubscher SG, Young LS, Niedobitek G, Murray PG: Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma. Virology 2003, 306:236-243
40. Ivers LC, Kim AY, Sax PE: Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis 2004, 38:1629-1632
41. Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, Bouabdallah R, Berger F, Delmer A, Coiffier B, Reyes F, Gaulard P: Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006, 108:4163-4169
42. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A: Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology 2007, 50:498-508
43. Tan BT, Warnke RA, Arber DA: The frequency of B- and T-cell gene rearrangements and Epstein-Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn 2006, 8:466-475; quiz 527
44. Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, Hamoudi RA, Munson P, Bacon CM, Dogan A, Du MQ: Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 2007, 138:44-53
45. Niedobitek G, Herbst H: In situ detection of Epstein-Barr virus and phenotype determination of EBV-infected cells. Methods Mol Biol 2006, 326:115-137
46. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, Whitby D, Barber GN, Dittmer DP, Harrington WJ Jr: Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005, 106:235-240
47. Bailout M, Germi R, Fafi-Kremer S, Guimet J, Bargues G, Seigneurin JM, Morand P: Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression. J Virol Methods 2007, 143:38-44
48. Kubota N, Wada K, Ito Y, Shimoyama Y, Nakamura S, Nishiyama Y, Kimura H: One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection. J Virol Methods 2008, 147:26-36
49. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Paramita DK, Fachiroh J, Adham M, Tan IB, Haryana SM, Middeldorp JM: Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 2006, 119:608-614
50. Hayes DP, Brink AA, Vervoort MB, Middeldorp JM, Meijer CJ, van den Brule AJ: Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol Pathol 1999, 52:97-103
51. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ: Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 2000, 60:2745-2748
52. Houali K, Wang X, Shimizu Y, Djennaoui D, Nicholls J, Fiorini S, Bouguermouh A, Ooka T: A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 2007, 13:4993-5000
53. Tong JH, Tsang RK, Lo KW, Woo JK, Kwong J, Chan MW, Chang AR, van Hasselt CA, Huang DP, To KF: Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res 2002, 8:2612-2619
54. Nicholls JM, Chua D, Chiu PM, Kwong DL: The detection of clinically occult nasopharyngeal carcinoma in patients following radiotherapy - an analysis of 69 patients. J Laryngol Otol 1996, 110:496-499
55. Delecluse HJ, Feederle R, O'Sullivan B, Taniere P: Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol 2007, 60:1358-1364
56. Hennard C, Pfuhl T, Buettner M, Becker KF, Knofel T, Middeldorp J, Kremmer E, Niedobitek G, Grasser F: The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J Pathol 2006, 209:430-435
57. Jebbink J, Bai X, Rogers BB, Dawson DB, Scheuermann RH, Domiati-Saad R: Development of real-time PCR assays for the quantitative detection of Epstein-Barr virus and cytomegalovirus, comparison of TaqMan probes, and molecular beacons. J Mol Diagn 2003, 5:15-20
58. Stevens SJ, Verkuijlen SA, Brule AJ, Middeldorp JM: Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens. J Clin Microbiol 2002, 40:3986-3992
59. Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, Wang JY, Twu CW, Liang KL, Chao J, Shen WC: Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:1342-1348
60. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, Yao JD, Wengenack NL, Rosenblatt JE, Cockerill FR 3rd, Smith TF: Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev 2006, 19:165-256
61. Fafi-Kremer S, Morand P, Barranger C, Bargues G, Magro S, Bes J, Bourgeois P, Joannes M, Seigneuhn JM: Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms. J Mol Diagn 2008, 10:78-84
62. Hill CE, Harris SB, Culler EE, Zimring JC, Nolte FS, Caliendo AM: Performance characteristics of two real-time PCR assays for the quantification of Epstein-Barr virus DNA. Am J Clin Pathol 2006, 125:665-671
63. Ruiz G, Pena P, de Ory F, Echevarria JE: Comparison of commercial real-time PCR assays for quantification of Epstein-Barr virus DNA. J Clin Microbiol 2005, 43:2053-2057
64. Perandin F, Cariani E, Pollara CP, Manca N: Comparison of commercial and in-house Real-time PCR assays for quantification of Epstein-Barr virus (EBV) DNA in plasma. BMC Microbiol 2007, 7:22
65. Hayden RT, Hokanson KM, Pounds SB, Bankowski MJ, Belzer SW, Carr J, Diorio D, Forman MS, Joshi Y, Hillyard D, Hodinka RL, Nikiforova MN, Romain CA, Stevenson J, Valsamakis A, Balfour HH Jr: Multicenter comparison of different real-time PCR assays for quantitative detection of epstein-barr virus. J Clin Microbiol 2008, 46:157-163
66. Cheng CC, Chang LY, Shao PL, Lee PI, Chen JM, Lu CY, Lee CY, Huang LM: Clinical manifestations and quantitative analysis of virus load in Taiwanese children with Epstein-Barr virus-associated infectious mononucleosis. J Microbiol Immunol Infect 2007, 40:216-221
67. Bauer CC, Aberle SW, Popow-Kraupp T, Kapitan M, Hofmann H, Puchhammer-Stockl E: Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection. J Med Virol 2005, 75:54-58
68. Yamashita N, Kimura H, Morishima T: Virological aspects of Epstein-Barr virus infections. Acta Med Okayama 2005, 59:239-246
69. Niesters HG: Molecular and diagnostic clinical virology in real time. Clin Microbiol Infect 2004, 10:5-11
70. Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA: On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 2008, 111:1420-1427
71. Piriou E, van Dort K, Otto S, van Oers MH, van Baarle D: Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection. Clin Infect Dis 2008, 46:313-316
72. Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, Imai S, Ohga S, Kanegane H, Tsuchiya S, Morio T, Mori M, Yokota S, Imashuku S: Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005, 80:64-69
73. Kimura H, Hoshino Y, Hara S, Sugaya N, Kawada J, Shibata Y, Kojima S, Nagasaka T, Kuzushima K, Morishima T: Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 2005, 191:531-539
74. Endo R, Yoshioka M, Ebihara T, Ishiguro N, Kikuta H, Kobayashi K: Clonal expansion of multiphenotypic Epstein-Barr virus-infected lymphocytes in chronic active Epstein-Barr virus infection. Med Hypotheses 2004, 63:582-587
75. Kimura H: Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 2006, 16:251-261
76. Mischler M, Fleming GM, Shanley TP, Madden L, Levine J, Castle V, Filipovich AH, Cornell TT: Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit. Pediatrics 2007, 119:e1212-e1218
77. Gulley ML, Amin MB, Nicholls JM, Banks PM, Ayala AG, Srigley JR, Eagan PA, Ro JY: Epstein-Barr virus is detected in undifferentiated nasopharyngeal carcinoma but not in lymphoepithelioma-like carcinoma of the urinary bladder. Hum Pathol 1995, 26:1207-1214
78. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, Liu FF: Prognostic significance of the Epstein-Barr virus, p53. Bcl-2, and survivin in nasopharyngeal cancer Clin Cancer Res 2006, 12:5726-5732
79. Bortolin MT, Pratesi C, Dolcetti R, Bidoli E, Vaccher E, Zanussi S, Tedeschi R, De Paoli P: Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett 2006, 233:247-254
80. Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM: Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003, 98:288-291
81. Lo YMD, Chan LYS, A.T.C. C, S.F. L, Lo KW, Zhang J, Lee JCK, Hjelm NM, Johnson PJ, Huang DP: Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999, 59:1188-1191
82. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS: Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350:2461-2470
83. Ma BB, King A, Lo YM, Yau YY, Zee B, Hui EP, Leung SF, Mo F, Kam MK, Ahuja A, Kwan WH, Chan AT: Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:714-720
84. Chan KC, Lo YM: Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA. Methods Mol Biol 2006, 336:111-121
85. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, Chan KC, Chan LY, Kwan WH, Lo YM, Chan AT: Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006, 24:5414-5418
86. Leung SF, Tam JS, Chan AT, Zee B, Chan LY, Huang DP, Van Hasselt A, Johnson PJ, Lo YM: Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004, 50:339-345
87. Yang X, Goldstein AM, Chen CJ, Rabkin CS, Chen JY, Cheng YJ, Hsu WL, Sun B, Diehl SR, Liu MY, Walters M, Shao W, Ortiz-Conde BA, Whitby D, Elmore SH, Gulley ML, Hildesheim A: Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer 2006, 118:780-784
88. To EW, Chan KC, Leung SF, Chan LY, To KF, Chan AT, Johnson PJ, Lo YM: Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 2003, 9:3254-3259
89. Lo YM, Leung SF, Chan LY, Chan AT, Lo KW, Johnson PJ, Huang DP: Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000, 60:2351-2355
90. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ: Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002, 94:1614-1619
91. Leung SF, Lo YM, Chan AT, To KF, To E, Chan LY, Zee B, Huang DP, Johnson PJ: Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. Clin Cancer Res 2003, 9:3431-3434
92. Zur Hausen A, van Rees BP, van Beek J, Craanen ME, Bloemena E, Offerhaus GJ, Meijer CJ, van den Brule AJ: Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol 2004, 57:487-491
93. Lo YM, Chan WY, Ng EK, Chan LY, Lai PB, Tam JS, Chung SC: Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 2001, 7:1856-1859
94. Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, Bucsky P: Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001, 72:1012-1019
95. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD: Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000, 38:712-715
96. Orentas RJ, Schauer DW Jr, Ellis FW, Walczak J, Casper JT, Margolis DA: Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant 2003, 7:305-314
97. D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L: Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transplant 2007, 13:343-348
98. Green M: Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001, 1:103-108
99. Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P: Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 2008, 27:100-105
100. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K: Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007, 39:235-244
101. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Haario H, Ruutu T, Hedman K: Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007, 45:1305-1309
102. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA: Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005, 5:2222-2228
103. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Lowenberg B, Cornelissen JJ: Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99:4364-4369
104. Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W: Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007, 83:433-438
105. Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, Pezzutto A, Riess H, Subklewe M: Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transplant Immunol 2007, 17:203-210
106. Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D: Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 2000, 182:1013-1021
107. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, Gee AP, Scott JD, Savoldo B: Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006, 20:689-694
108. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM: Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002, 73:1603-1610
109. Weinberger B, Plentz A, Weinberger KM, Hahn J, Holler E, Jilg W: Quantitation of Epstein-Barr virus mRNA using reverse transcription and real-time PCR. J Med Virol 2004, 74:612-618
110. Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N, Rickinson AB, Leiner I, Pamer E, Lowenberg B, Cornelissen JJ, Gratama JW: Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003, 101:4290-4297
111. Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C: Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis 2003, 188:1853-1864
112. Gandhi MK, Wilkie GM, Dua U, Mollee PN, Grimmett K, Williams T, Whitaker N, Gill D, Crawford DH: Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007, 7:1293-1299
113. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH: Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131
114. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE: Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006, 108:2942-2949
115. van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC, Boucher CA, Gratama JW, Budel LM, van der Holt B, van Loon AM, Lowenberg B, Verdonck LF, Cornelissen JJ: Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br Journal of Haematol 2001, 113:814-821
116. Gulley ML, Swinnen LJ, Plaisance KT Jr, Schnell C, Grogan TM, Schneider BG: Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003, 76:959-964
117. Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koeter G, The TH, van Der Bij W: Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002, 73:100-104
118. Buettner M, Greiner A, Avramidou A, Jack HM, Niedobitek G: Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Hematol Oncol 2005, 23:127-132
119. Schauer E, Webber S, Green M, Rowe D: Surface immunoglobulin-deficient Epstein-Barr virus-infected B cells in the peripheral blood of pediatric solid-organ transplant recipients. J Clin Microbiol 2004, 42:5802-5810
120. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R: Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006, 118:1853-1861
121. Takakuwa T, Tresnasari K, Rahadiani N, Miwa H, Daibata M, Aozasa K: Cell origin of pyothorax-associated lymphoma: a lymphoma strongly associated with Epstein-Barr virus infection. Leukemia 2008, 22:620-627
122. Swerdlow SH: T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol 2007, 127:887-895
123. Bakker NA, Verschuuren EA, Veeger NJ, van der Bij W, van Imhoff GW, Kallenberg CG, Hepkema BG: Quantification of Epstein-Barr virus-DNA load in lung transplant recipients: a comparison of plasma versus whole blood. J Heart Lung Transplant 2008, 27:7-10
124. Stevens SJ, Pronk I, Middeldorp JM: Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001, 39:1211-1216
125. Wada K, Kubota N, Ito Y, Yagasaki H, Kato K, Yoshikawa T, Ono Y, Ando H, Fujimoto Y, Kiuchi T, Kojima S, Nishiyama Y, Kimura H: Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay. J Clin Microbiol 2007, 45:1426-1432
126. Matsukura T, Yokoi A, Egawa H, Kudo T, Kawashima M, Hirata Y, Tanaka H, Kagajo K, Wada H, Tanaka K: Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation. Clin Transplant 2002, 16:107-112
127. Wadowsky RM, Laus S, Green M, Webber SA, Rowe D: Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003, 41:5245-5249
128. Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dorken B, Riess H, Gartner B: Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 2006, 85:478-484
129. Humar A, Michaels M: American Society of Transplantation recommendations
130. European Best Practice Guidelines for Renal Transplantation: Section IV: Long-term management of the transplant recipient. IV. 6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002, 17(Suppl 4):31-33, 35-36
131. Ahya VN, Douglas LP, Andreadis C, Arnoldi S, Svoboda J, Kotloff RM, Hadjiliadis D, Sager JS, Woo YJ, Pochettino A, Schuster SJ, Stadtmauer EA, Tsai DE: Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant 2007, 26:839-844
132. Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M, Wadowsky RM, Rowe DT, Webber SA: Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008, 8:442-445
133. Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, Salvatierra O Jr, Sarwal MM: Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007, 11:187-195
134. Wagner HJ, Schlager F, Claviez A, Bucsky P: Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction. Eur J Cancer 2001, 37:1853-1857
135. Au WY, Pang A, Choy C, Chim CS, Kwong YL: Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004, 104:243-249
136. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, Prince HM, Wolf M, Clarke K, Underhill C, Mills T, Mollee P, Gill D, Marlton P, Seymour JF, Khanna R: Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006, 12:460-464
137. Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, Gulley ML: Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 2005, 75:59-69
138. Stevens SJ, Smits PH, Verkuijlen SA, Rockx DA, van Gorp EC, Mulder JW, Middeldorp JM: Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. AIDS 2007, 21:2141-2149
139. Bonnet F, Jouvencel AC, Parrens M, Leon MJ, Cotto E, Garrigue I, Morlat P, Beylot J, Fleury H, Lafon ME: A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 2006, 36:258-263
140. Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevlever G, Teyssie AR, Benetucci J, Picconi MA: Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis 2007, 11:172-178
141. Bossolasco S, Falk KI, Ponzoni M, Ceserani N, Crippa F, Lazzarin A, Linde A, Cinque P: Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis 2006, 42:e21-25
142. Antinori A, De Rossi G, Ammassari A, Cingolani A, Murri R, Di Giuda D, De Luca A, Pierconti F, Tartaglione T, Scerrati M, Larocca LM, Ortona L: Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999, 17:554-560
143. Antinori A, Cingolani A, De Luca A, Gaidano G, Ammassari A, Larocca LM, Ortona L: Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Ann Neurol 1999, 45:259-261
144. Israel BF, Kenney SC: Virally targeted therapies for EBV-associated malignancies. Oncogene 2003, 22:5122-5130
145. Hsieh PP, Tung CL, Chan AB, Liao JB, Wang JS, Tseng HH, Su HH, Chang KC, Chang CC: EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. Am J Clin Pathol 2007, 128:579-584
146. Yap YY, Hassan S, Chan M, Choo PK, Ravichandran M: Epstein-Barr virus DNA detection in the diagnosis of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 2007, 136:986-991